Biotech Digest – INSM Reports Positive Data, MRK Gets EC Approval, LCI Receives FDA Approval

Oramed Pharmaceuticals reported the successful conclusion of its meeting with the FDA with regard to its drug candidate ORMD-0801. Insmed (INSM) stock jumped over 100 percent in the pre-market session.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.